Cover Image
Market Research Report

Custom Antibody Market by Service (Antibody Production, Characterization, Immunization, Fragmentation), Type (Monoclonal, Polyclonal, Recombinant), Source (Mouse, Rabbit), Research Area (Oncology, Immunology), and End Users - Global Forecast to 2023

Published by MarketsandMarkets Product code 760885
Published Content info 198 Pages
Delivery time: 1-2 business days
Price
Back to Top
Custom Antibody Market by Service (Antibody Production, Characterization, Immunization, Fragmentation), Type (Monoclonal, Polyclonal, Recombinant), Source (Mouse, Rabbit), Research Area (Oncology, Immunology), and End Users - Global Forecast to 2023
Published: December 19, 2018 Content info: 198 Pages
Description

"The global custom antibody market is projected to grow at a CAGR of 8.9%."

The custom antibody market is expected to reach USD 481 million by 2023 from an estimated USD 313 million in 2018, at a CAGR of 8.9%. Increase in research activities (especially in the life sciences industry), growing industry-academia collaborations, and the expanding antibody therapeutics pipeline are the primary growth drivers for this market. Rapid growth in developing countries across APAC and Latin America and the increasing demand for personalized medicine and protein therapeutics are expected to offer significant growth opportunities for players in this market. However, the need for steep capital investments and long duration of antibody development, along with the increasing focus on antibody alternatives for proteomic studies, are some of the major market challenges.

"Antibody production & purification segment to grow at the highest rate during the forecast period."

On the basis of services, the custom antibody market is segmented into antibody development, antibody production & purification, and antibody fragmentation & labeling. The antibody production & purification segment is projected to witness the highest growth in the custom antibody services market during the forecast period. Growth in this segment is largely driven by the need for high-quality antibodies for research reproducibility and generating high-quality therapeutics.

"The recombinant antibodies segment is expected to grow at the highest CAGR during the forecast period."

Based on type, custom antibodies are categorized as monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and other custom antibodies. The recombinant antibodies segment is projected to witness the highest growth rate during the forecast period. The increasing development of recombinant antibodies due to their advantages such as batch-to-batch reproducibility, rapid production along with their capability of data reproducibility within research is propelling the growth of this segment during the forecast period.

"APAC is projected to witness the highest growth during the forecast period."

Even though North America is expected to account for the largest share of the global custom antibody market in 2018, APAC is expected to witness the highest CAGR during the forecast period. The growing Asian scientific base and capability, growing proteomics and genomics research and increasing research funding, increasing investments by pharmaceutical and biotechnology companies, growing awareness about personalized therapeutics, and increasing research activities in the field of mAb-based therapeutics are factors driving the growth of this regional segment.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-48%, Tier 2-34%, and Tier 3-18%
  • By Designation: C-level-42%, Director Level-40%, and Others-18%
  • By Region: North America-35%, Europe-25%, Asia Pacific-30%, Row - 7%

The prominent players in the global custom antibody market are: Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), Merck Group (Germany), Abcam plc (UK), Cell Signaling Technology, Inc. (US), Agilent Technologies, Inc. (US), GenScript (US), BioLegend, Inc. (US), Rockland Immunochemicals (US), ProMab Biotechnologies (US), Innovagen AB (Sweden), and ProteoGenix (US).

Research Coverage:

The report analyzes the market for various custom antibody services and their adoption pattern. It aims at estimating the market size and future growth potential of the global custom antibody market and different segments such as service, type, source, research area, end user, and regions. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, product & service offerings, and recent developments.

Reasons to Buy the Report:

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening their market presence.

This report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global custom antibody market
  • Product & Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product or service launches in the global custom antibody market
  • Market Development: Comprehensive information on the lucrative emerging regions by service, type, source, research area, end user, and region
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global custom antibody market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, revenue analysis, and products & services of leading players in the global custom antibody market
Table of Contents
Product Code: BT 6817

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKETS COVERED
    • 1.3.2. YEARS CONSIDERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. STAKEHOLDERS
  • 1.6. LIMITATIONS

2. RESEARCH METHODOLOGY

  • 2.1. RESEARCH APPROACH
    • 2.1.1. SECONDARY RESEARCH
      • 2.1.1.1. Key data from secondary sources
    • 2.1.2. PRIMARY RESEARCH
      • 2.1.2.1. Key data from primary sources
      • 2.1.2.2. Break down of primaries
      • 2.1.2.3. Key industry insights
  • 2.2. MARKET SIZE ESTIMATION
  • 2.3. DATA TRIANGULATION APPROACH
  • 2.4. MARKET SHARE ESTIMATION
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. CUSTOM ANTIBODIES: MARKET OVERVIEW
  • 4.2. CUSTOM ANTIBODIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.3. REGIONAL MIX: CUSTOM ANTIBODIES MARKET (2018-2023)
  • 4.4. CUSTOM ANTIBODIES MARKET: DEVELOPED VS. DEVELOPING MARKETS, 2018 VS. 2023

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. MARKET DRIVERS
      • 5.2.1.1. Increasing research activity and funding
      • 5.2.1.2. Quality concerns over catalog antibodies
      • 5.2.1.3. Increasing antibody therapeutics and expanding drug pipeline
      • 5.2.1.4. Growing industry-academia collaborations
    • 5.2.2. MARKET OPPORTUNITIES
      • 5.2.2.1. High growth opportunities in emerging countries
      • 5.2.2.2. Increasing demand for personalized medicine and protein therapeutics
      • 5.2.2.3. Growth in stem cell and CVD research
      • 5.2.2.4. Increasing focus on biomarker discovery
    • 5.2.3. MARKET CHALLENGES
      • 5.2.3.1. Cost- and time-intensive antibody development processes
      • 5.2.3.2. Presence of antibody alternatives
    • 5.2.4. INDUSTRY TRENDS
      • 5.2.4.1. Increasing focus on antibody-drug conjugates (ADCs)
      • 5.2.4.2. Development of bispecific antibodies

6. CUSTOM ANTIBODY MARKET, BY SERVICE

  • 6.1. INTRODUCTION
  • 6.2. ANTIBODY DEVELOPMENT
    • 6.2.1. ANTIBODY CHARACTERIZATION
      • 6.2.1.1. Characterization eliminates antibodies with heterogeneities that may hamper research studies; this is driving market growth
    • 6.2.2. ANTIGEN PREPARATION
      • 6.2.2.1. Antigen preparation forms one of the most important steps in the antibody production process
    • 6.2.3. IMMUNIZATION & HYBRIDOMA PRODUCTION
      • 6.2.3.1. Specific immunization protocols are followed depending on the antibody required and animal used to generate them
  • 6.3. ANTIBODY PRODUCTION & PURIFICATION
  • 6.4. ANTIBODY FRAGMENTATION & LABELING

7. CUSTOM ANTIBODY MARKET, BY TYPE

  • 7.1. INTRODUCTION
  • 7.2. MONOCLONAL ANTIBODIES
    • 7.2.1. MONOCLONAL ANTIBODIES TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
  • 7.3. POLYCLONAL ANTIBODIES
    • 7.3.1. POLYCLONAL ABS ARE PREFERRED IN PROTEOMIC RESEARCH FOR DETECTION OF DENATURED PROTEINS
  • 7.4. RECOMBINANT ANTIBODIES
    • 7.4.1. RESEARCH REPRODUCIBILITY OFFERED BY THESE ANTIBODIES IS DRIVING THE GROWTH OF THE RECOMBINANT ANTIBODIES SEGMENT
  • 7.5. OTHER CUSTOM ANTIBODIES

8. CUSTOM ANTIBODY MARKET, BY SOURCE

  • 8.1. INTRODUCTION
  • 8.2. MICE
    • 8.2.1. MICE ARE THE MOST PREFERRED HOSTS FOR MONOCLONAL ANTIBODY PRODUCTION
  • 8.3. RABBITS
    • 8.3.1. ANTIBODIES DEVELOPED IN RABBITS ELIMINATE THE LIMITATION OF SELF-ANTIGEN RECOGNITION IN HUMANS
  • 8.4. OTHER SOURCES

9. CUSTOM ANTIBODY MARKET, BY RESEARCH AREA

  • 9.1. INTRODUCTION
  • 9.2. ONCOLOGY
    • 9.2.1. USE OF ANTIBODIES HAS GROWN CONSIDERABLY IN CANCER RESEARCH
  • 9.3. INFECTIOUS DISEASES
    • 9.3.1. ANTIBODIES ARE WIDELY USED IN R&D FOR THE DEVELOPMENT OF VACCINES & THERAPEUTICS AGAINST VARIOUS INFECTIOUS DISEASES
  • 9.4. IMMUNOLOGY
    • 9.4.1. ASSESSMENT OF CELL SURFACE ANTIGENS USING ANTIBODIES FORMS AN IMPORTANT FIELD OF RESEARCH IN IMMUNOLOGY
  • 9.5. NEUROBIOLOGY
    • 9.5.1. NEUROBIOLOGY FORMS ONE OF THE FASTEST-GROWING SEGMENTS IN TERMS OF RESEARCH BEING UNDERTAKEN UTILIZING ANTIBODIES
  • 9.6. STEM CELLS
    • 9.6.1. AVAILABILITY OF HIGH-QUALITY ANTIBODIES HAS BOOSTED STEM CELL RESEARCH
  • 9.7. CARDIOVASCULAR DISEASES
    • 9.7.1. IDENTIFICATION & CHARACTERIZATION OF CVD BIOMARKERS IS AN IMPORTANT RESEARCH AREA UTILIZING ANTIBODIES
  • 9.8. OTHER RESEARCH AREAS

10. CUSTOM ANTIBODY MARKET, BY END USER

  • 10.1. INTRODUCTION
  • 10.2. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.2.1. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE THE LARGEST END USERS OF CUSTOM ANTIBODIES
  • 10.3. ACADEMIC & RESEARCH INSTITUTES
    • 10.3.1. INCREASE IN DNA SEQUENCING STUDIES AND PROTEOMIC RESEARCH TO DRIVE MARKET GROWTH
  • 10.4. CONTRACT RESEARCH ORGANIZATIONS
    • 10.4.1. CROS PROVIDE AFFORDABLE OUTLETS FOR COMPANIES AND ACADEMIA TO PURSUE NEW MEDICINES AND OFFER A COST-EFFECTIVE SOLUTION TO DEVELOP DRUGS

11. CUSTOM ANTIBODY MARKET, BY REGION

  • 11.1. INTRODUCTION
  • 11.2. NORTH AMERICA
    • 11.2.1. US
      • 11.2.1.1. Growing research in the field of structure-based drug design and therapeutic mAbs to drive market growth
    • 11.2.2. CANADA
      • 11.2.2.1. Increasing genomic research to drive the adoption of custom antibodies in the coming years
  • 11.3. EUROPE
    • 11.3.1. GERMANY
      • 11.3.1.1. High investments for the development of ADCs support the growth of the custom antibodies market in Germany
    • 11.3.2. UK
      • 11.3.2.1. Growing research investments to drive growth in the life science research market, resulting in the growing use of antibodies
    • 11.3.3. FRANCE
      • 11.3.3.1. Expanding pipeline of therapeutic mAbs along with increasing investments in research are supporting market growth
    • 11.3.4. ITALY
      • 11.3.4.1. Growing proteomics and genomics research at the academic level to play a key role in market growth in Italy
    • 11.3.5. SPAIN
      • 11.3.5.1. Increasing focus on the advancement of translational personalized medicine is expected to drive market growth
    • 11.3.6. REST OF EUROPE
  • 11.4. ASIA PACIFIC
    • 11.4.1. JAPAN
      • 11.4.1.1. Large number of research initiatives towards the development of various ADCs support market growth in Japan
    • 11.4.2. CHINA
      • 11.4.2.1. China is one of the fastest-growing markets in the research sector and is expected to dominate the market in the coming years
    • 11.4.3. INDIA
      • 11.4.3.1. Research for generic mAbs and fusion mAbs as therapeutics is expected to propel the custom antibodies market in the country
    • 11.4.4. REST OF ASIA PACIFIC
  • 11.5. LATIN AMERICA
    • 11.5.1. INCREASING APPLICATIONS OF RESEARCH-SPECIFIC CUSTOM ANTIBODIES TO DRIVE THE GROWTH OF THE MARKET IN THE REGION
  • 11.6. MIDDLE EAST & AFRICA
    • 11.6.1. GROWING FOCUS OF PHARMACEUTICAL COMPANIES ON THE AFRICAN MARKET IS DRIVING THE MARKET FOR CUSTOM ANTIBODIES IN THE REGION

12. COMPETITIVE LANDSCAPE

  • 12.1. OVERVIEW
  • 12.2. MARKET SHARE ANALYSIS
  • 12.3. COMPETITIVE SITUATION AND TRENDS
    • 12.3.1. PRODUCT & SERVICES LAUNCHES
    • 12.3.2. EXPANSIONS
    • 12.3.3. ACQUISITIONS
    • 12.3.4. OTHER STRATEGIES

13. COMPANY PROFILES (Business Overview, Services Offered, Recent Developments, SWOT Analysis, MnM View)*

  • 13.1. THERMO FISHER SCIENTIFIC INC.
  • 13.2. GENSCRIPT
  • 13.3. ABCAM PLC
  • 13.4. MERCK GROUP
  • 13.5. BIO-RAD LABORATORIES, INC.
  • 13.6. CELL SIGNALING TECHNOLOGY, INC.
  • 13.7. AGILENT TECHNOLOGIES, INC.
  • 13.8. BIOLEGEND, INC.
  • 13.9. ROCKLAND IMMUNOCHEMICALS INC.
  • 13.10. PROMAB BIOTECHNOLOGIES, INC.
  • 13.11. PROTEOGENIX
  • 13.12. INNOVAGEN AB

*Business Overview, Services Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

14. APPENDIX

  • 14.1. INSIGHTS OF INDUSTRY EXPERTS
  • 14.2. DISCUSSION GUIDE
  • 14.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 14.4. AVAILABLE CUSTOMIZATIONS
  • 14.5. RELATED REPORTS
  • 14.6. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: MARKET DRIVERS: IMPACT ANALYSIS
  • TABLE 2: MARKET OPPORTUNITIES: IMPACT ANALYSIS
  • TABLE 3: MARKET CHALLENGES: IMPACT ANALYSIS
  • TABLE 4: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 5: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 6: ANTIBODY DEVELOPMENT MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 7: ANTIBODY CHARACTERIZATION MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 8: ANTIGEN PREPARATION MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 9: IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 10: ANTIBODY PRODUCTION & PURIFICATION MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 11: ANTIBODY FRAGMENTATION & LABELING MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 12: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 13: CUSTOM MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 14: CUSTOM POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 15: CUSTOM RECOMBINANT ANTIBODIES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 16: OTHER CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 17: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 18: CUSTOM ANTIBODIES MARKET FOR MICE, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 19: CUSTOM ANTIBODIES MARKET FOR RABBITS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 20: CUSTOM ANTIBODIES MARKET FOR OTHER SOURCES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 21: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 22: CUSTOM ANTIBODIES MARKET FOR ONCOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 23: CUSTOM ANTIBODIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 24: CUSTOM ANTIBODIES MARKET FOR IMMUNOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 25: CUSTOM ANTIBODIES MARKET FOR NEUROBIOLOGY, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 26: CUSTOM ANTIBODIES MARKET FOR STEM CELLS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 27: CUSTOM ANTIBODIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 28: CUSTOM ANTIBODIES MARKET FOR OTHER RESEARCH AREAS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 29: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 30: CUSTOM ANTIBODIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 31: CUSTOM ANTIBODIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 32: CUSTOM ANTIBODIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 33: CUSTOM ANTIBODIES MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 34: NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 35: NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 36: NORTH AMERICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 37: NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 38: NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 39: NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 40: NORTH AMERICA: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 41: US: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 42: US: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 43: US: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 44: US: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 45: US: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 46: US: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 47: CANADA: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 48: CANADA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 49: CANADA: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 50: CANADA: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 51: CANADA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 52: CANADA: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 53: EUROPE: CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 54: EUROPE: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 55: EUROPE: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 56: EUROPE: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 57: EUROPE: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 58: EUROPE: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 59: EUROPE: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 60: GERMANY: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 61: GERMANY: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 62: GERMANY: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 63: GERMANY: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 64: GERMANY: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 65: GERMANY: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 66: UK: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 67: UK: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 68: UK: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 69: UK: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 70: UK: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 71: UK: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 72: FRANCE: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 73: FRANCE: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 74: FRANCE: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 75: FRANCE: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 76: FRANCE: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 77: FRANCE: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 78: ITALY: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 79: ITALY: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 80: ITALY: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 81: ITALY: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 82: ITALY: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 83: ITALY: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 84: SPAIN: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 85: SPAIN: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 86: SPAIN: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 87: SPAIN: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 88: SPAIN: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 89: SPAIN: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 90: ROE: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 91: ROE: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 92: ROE: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 93: ROE: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 94: ROE: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 95: ROE: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 96: ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 97: ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 98: ASIA PACIFIC: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 99: ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 100: ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 101: ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 102: ASIA PACIFIC: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 103: JAPAN: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 104: JAPAN: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 105: JAPAN: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 106: JAPAN: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 107: JAPAN: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 108: JAPAN: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 109: CHINA: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 110: CHINA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 111: CHINA: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 112: CHINA: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 113: CHINA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 114: CHINA: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 115: INDIA: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 116: INDIA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 117: INDIA: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 118: INDIA: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 119: INDIA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 120: INDIA: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 121: ROAPAC: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 122: ROAPAC: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 123: ROAPAC: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 124: ROAPAC: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 125: ROAPAC: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 126: ROAPAC: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 127: LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 128: LATIN AMERICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 129: LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 130: LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 131: LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 132: LATIN AMERICA: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 133: MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2016-2023 (USD MILLION)
  • TABLE 134: MIDDLE EAST & AFRICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 135: MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 136: MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2016-2023 (USD MILLION)
  • TABLE 137: MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2016-2023 (USD MILLION)
  • TABLE 138: MIDDLE EAST & AFRICA: CUSTOM ANTIBODIES MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 139: CUSTOM ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2017
  • TABLE 140: PRODUCT AND SERVICE LAUNCHES, 2015-2018
  • TABLE 141: EXPANSIONS, 2015-2018
  • TABLE 142: ACQUISITIONS, 2015-2018
  • TABLE 143: OTHER STRATEGIES, 2015-2018

LIST OF FIGURES

  • FIGURE 1: CUSTOM ANTIBODY MARKET
  • FIGURE 2: RESEARCH DESIGN
  • FIGURE 3: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATIONS, AND REGION
  • FIGURE 4: BOTTOM-UP APPROACH
  • FIGURE 5: TOP-DOWN APPROACH
  • FIGURE 6: DATA TRIANGULATION METHODOLOGY
  • FIGURE 7: CUSTOM ANTIBODIES MARKET, BY SERVICE, 2018 VS. 2023 (USD MILLION)
  • FIGURE 8: CUSTOM ANTIBODIES MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION)
  • FIGURE 9: CUSTOM ANTIBODIES MARKET, BY SOURCE, 2018 VS. 2023 (USD MILLION)
  • FIGURE 10: CUSTOM ANTIBODIES MARKET, BY RESEARCH AREA, 2018 VS. 2023 (USD MILLION)
  • FIGURE 11: CUSTOM ANTIBODIES MARKET, BY END USER, 2018 VS. 2023 (USD MILLION)
  • FIGURE 12: GEOGRAPHICAL SNAPSHOT OF THE CUSTOM ANTIBODIES MARKET
  • FIGURE 13: QUALITY CONCERNS OVER CATALOG ANTIBODIES & THE EXPANDING AB THERAPEUTICS PIPELINE TO DRIVE MARKET GROWTH
  • FIGURE 14: US DOMINATED THE CUSTOM ANTIBODIES MARKET IN 2017
  • FIGURE 15: APAC TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2018-2023)
  • FIGURE 16: DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE BETWEEN 2018 & 2023
  • FIGURE 17: CUSTOM ANTIBODIES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 18: R&D INVESTMENTS, BY COUNTRY (USD BILLION)
  • FIGURE 19: NUMBER OF THERAPEUTIC ANTIBODIES APPROVED FOR MARKET RELEASE (2011-2017)
  • FIGURE 20: PERSONALIZED MEDICINE PRODUCTS, 2008-2016
  • FIGURE 21: INCREASING FOCUS ON ADCS & THE DEVELOPMENT OF BISPECIFIC ANTIBODIES ARE THE KEY MARKET TRENDS
  • FIGURE 22: ANTIBODY DEVELOPMENT SERVICES TO DOMINATE THE CUSTOM ANTIBODIES MARKET DURING THE FORECAST PERIOD
  • FIGURE 23: RECOMBINANT ANTIBODIES SEGMENT IS EXPECTED TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD
  • FIGURE 24: ONCOLOGY TO DOMINATE THE CUSTOM ANTIBODIES MARKET DURING THE FORECAST PERIOD
  • FIGURE 25: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE THE CUSTOM ANTIBODIES MARKET DURING THE FORECAST PERIOD
  • FIGURE 26: CUSTOM ANTIBODIES MARKET: GEOGRAPHIC SNAPSHOT (2017)
  • FIGURE 27: NORTH AMERICA: CUSTOM ANTIBODIES MARKET SNAPSHOT
  • FIGURE 28: EUROPE: CUSTOM ANTIBODIES MARKET SNAPSHOT
  • FIGURE 29: ASIA PACIFIC: CUSTOM ANTIBODIES MARKET SNAPSHOT
  • FIGURE 30: EXPANSIONS-KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2015 TO OCTOBER 2018
  • FIGURE 31: THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • FIGURE 32: GENSCRIPT: COMPANY SNAPSHOT
  • FIGURE 33: ABCAM PLC: COMPANY SNAPSHOT
  • FIGURE 34: MERCK GROUP: COMPANY SNAPSHOT
  • FIGURE 35: BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • FIGURE 36: AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
Back to Top